The factors such as increased usage of biomarkers in cancer treatment, growing efforts towards drug discovery, wide application of biomarkers in personalized medicine and diagnostics, initiatives taken towards biomarker research are furthermore boosting the growth of the global biomarkers market.
- Advertising -
Global Biomarker Market is expected to reach USD 85,927.95 million by 2024 from USD 28,091.78 million in 2016, at a CAGR of 15.1%. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
On the other hand, high capital investment may hinder the growth of the market. The biomarker market in the Global region is leading in North America.
- Advertising -
Market Segmentation: Global Biomarkers Market
- The global biomarker market is segmented on the basis of product type, technology, application and indication. The global biomarkers market is segmented based on product type into three notable segments; consumables, services and software. In 2017, consumables segment is expected to dominate the global biomarkers market with 58.6% market share and is expected to reach USD 51,156.05 million by 2024, with the highest CAGR of 15.4% in the forecast period 2017 to 2024.
- On the basis of technology, global biomarker market is segmented into three notable segments; safety biomarkers, efficacy biomarkers and validation biomarkers. In 2017, safety biomarkers is expected to dominate the global biomarkers market with 47.8% market share and is expected to reach USD 41,933.30 million by 2024, with the highest CAGR of 15.4% in the forecast period 2017 to 2024.
- On the basis of application, global biomarker market is segmented into diagnostics development, drug discovery and development, personalized medicine, disease-risk assessment, and others. In 2017, diagnostic development is expected to dominate the market with the market share of 35.4% the market is expected to reach USD 29,148.7 million by 2024, growing at a CAGR of 14.4% in the forecast period 2017 to 2024. However, personalized medicine is expected to grow at the highest CAGR of 16.2% in the forecast period, and is expected to reach USD 19,520.5 million in 2024 from USD 5,901.5 million in 2016.
- The Global biomarkers market is segmented based on indication into four notable segments; cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others diseases. In 2017, cancer is expected to dominate the global biomarkers market with 38.0% market share and is expected to reach USD 32,632.11 million by 2024, with a CAGR of 15.1% in the forecast period 2017 to 2024. However, cardiovascular disorders is expected to grow at the highest CAGR of 15.9% in the forecast period, and is expected to reach USD 25,063.53 million in 2024 from USD 7,736.13 million in 2016
BIO-RAD LABORATORIES INC.:
Founded in 1952 and headquartered in California, U.S. Bio-Rad laboratories, Inc. develops and commercializes the wide range of products and systems in the healthcare, life science research, analytical chemistry and few other areas, which is used for the separation of composite chemical and biological ingredients and for the analysis and purification of their components.
Bio-Rad operates its business in two industry segments named as life science and clinical diagnostics. Clinical Diagnostics segment manufactures, commercializes informatics systems, test systems, test kits and quality controls for the clinical laboratories.
Bio-rad has its presence across the globe in United States, Australia, Greece, Portugal, Austria, Hong Kong, Russia, Belgium, France, Hungary, South Africa, Singapore, Brazil, India, Canada, Israel, South Korea, China, Italy, Spain, Czech Republic, Japan, Sweden, Denmark, Netherlands, Mexico, Switzerland, Egypt, Taiwan, Finland, New Zealand, Thailand, Norway, United Kingdom, Germany, and Poland.
Incorporated in 1947 and headquartered in Massachusetts, U.S. PerkinElmer, Inc. is a supplier and manufacturer of products, services and solutions for the food, diagnostics, industrial, environmental, life sciences research and laboratory services markets.
The company operates its business through two business segments which includes discovery & analytical solutions and diagnostics. The diagnostics segment provides products and wide range of reagents, instruments, assay platforms, and software for hospitals, medical labs, clinicians, and medical research professionals.
The segment focusses on the areas such as reproductive health, developing market diagnostics, and applied genomics.
PerkinElmer develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceutical products which are marketed directly or indirectly in U.S. and across the globe. The company commercializes products and services in over 150 countries.
Founded in 1984 and headquartered at Hilden, Germany, Qiagen is engaged in sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company operates through different business segments, namely Next-Gen Sequencing, Molecular Diagnostic, Life Sconce Research, Animal and Vet.
Testing, Bioinformatics and others. The molecular diagnostic segment includes Oncology, Infectious Disease, Tuberculosis Management, Transplantation Testing and Women’s health.
Next-Gen Sequencing covers GeneReader NGS System and QIAseq NGS Solutions.
Qiagen has its operations across the North America, Europe, Middle East and Africa, Asia-Pacific and rest of world. Some of its subsidiaries include Exiqon (Denmark), Cellestis (Australia), Tiangen Biotech Co.
Ltd. (Beijing), Qiagen Ltd. (India), Ipsogen SA (France) and many more subsidiaries across the globe.
Access Report: databridgemarketresearch.com/speak…biomarkers-market
Key Drivers: Global Biomarkers Market
Global biomarker market is growing with the increased usage of biomarkers in cancer treatment, growing efforts towards drug discovery, wide application of biomarkers in personalized medicine and diagnostics, initiatives taken towards biomarker research are furthermore boosting the growth of the global biomarkers market.
Table Of Contents
1.1. Objectives Of The Study
1.2. Market Definition
1.3. Overview Of Global Biomarkers Market
1.4. Currency And Pricing
1.6. Markets Covered
- Market Segmentation
2.1. Markets Covered
2.2. Geographic Scope
2.3. Years Considered For The Study
2.4. Currency And Pricing
2.5. Research Methodology
2.6. Primary Interviews With Key Opinion Leaders
2.7. Secondary Sources
- Market Overview
3.1.1. Increased Usage Of Biomarkers In Cancer Treatment
3.1.2. Growing Efforts Towards Drug Discovery
3.1.3. Wide Application Of Biomarkers In Personalized Medicine And Diagnostics
3.1.4. Initiatives Taken Towards Biomarker Research
3.2.1. Unfavourable Reimbursement Systems
3.2.2. High Capital Investments
3.2.3. High Costing Involved In Sample Collection And Storage
3.3.1. Emerging Economies
3.4.1. Demonstrating The Clinical Validity In Biomarker-Based Tests
- Executive Summary
- Premium Insights
Want Full Report? databridgemarketresearch.com/inqui…biomarkers-market
Category: Market Research Publishers and RetailersCompany about: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wi ...
For more information: